Literature DB >> 21885831

Autologous mesenchymal stem cells mobilize cKit+ and CD133+ bone marrow progenitor cells and improve regional function in hibernating myocardium.

Gen Suzuki1, Vijay Iyer, Te-Chung Lee, John M Canty.   

Abstract

RATIONALE: Mesenchymal stem cells (MSCs) improve function after infarction, but their mechanism of action remains unclear, and the importance of reduced scar volume, cardiomyocyte proliferation, and perfusion is uncertain.
OBJECTIVE: The present study was conducted to test the hypothesis that MSCs mobilize bone marrow progenitor cells and improve function by stimulating myocyte proliferation in collateral-dependent hibe rnating myocardium. METHODS AND
RESULTS: Swine with chronic hibernating myocardium received autologous intracoronary MSCs (icMSCs; ≈44 ×10(6) cells, n = 10) 4 months after instrumentation and were studied up to 6 weeks later. Physiological and immunohistochemical findings were compared with untreated hibernating animals (n = 7), sham-normal animals (n = 5), and icMSC-treated sham-normal animals (n = 6). In hibernating myocardium, icMSCs increased function (percent wall thickening of the left anterior descending coronary artery 24 ± 4% to 43 ± 5%, P < 0.05), although left anterior descending coronary artery flow reserve (adenosine/rest) remained critically impaired (1.2 ± 0.1 versus 1.2 ± 0.1). Circulating cKit+ and CD133+ bone marrow progenitor cells increased transiently after icMSC administration, with a corresponding increase in myocardial cKit+/CD133+ and cKit+/CD133- bone marrow progenitor cells (total cKit+ from 223 ± 49 to 4415 ± 866/10(6) cardiomyocytes, P < 0.05). In hibernating hearts, icMSCs increased Ki67+ cardiomyocytes (from 410 ± 83 to 2460 ± 610/10(6) nuclei, P < 0.05) and phospho-histone H3-positive cardiomyocytes (from 9 ± 5 to 116 ± 12/10(6) nuclei, P < 0.05). Myocyte nuclear number (from 75 336 ± 5037 to 114 424 ± 9564 nuclei/mm3, P < 0.01) and left ventricular mass (from 2.5 ± 0.1 to 2.8 ± 0.1 g/kg, P < 0.05) increased, yet myocytes were smaller (14.5 ± 0.4 versus 16.5 ± 0.4 μm, P < 0.05), which supports endogenous cardiomyocyte proliferation. In sham-normal animals, icMSCs increased myocardial bone marrow progenitor cells with no effect on myocyte proliferation or regional function.
CONCLUSIONS: Our results indicate that icMSCs improve function in hibernating myocardium independent of coronary flow or reduced scar volume. This arises from stimulation of myocyte proliferation with increases in cKit+/CD133+ bone marrow progenitor cells and cKit+/CD133- resident stem cells, which increase myocyte number and reduce cellular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21885831     DOI: 10.1161/CIRCRESAHA.111.245969

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  49 in total

1.  Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair.

Authors:  David Zisa; Arsalan Shabbir; Michalis Mastri; Tyler Taylor; Ilija Aleksic; Mary McDaniel; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-30       Impact factor: 4.733

2.  Bioenergetic and functional consequences of cellular therapy: activation of endogenous cardiovascular progenitor cells.

Authors:  Qiang Xiong; Lei Ye; Pengyuan Zhang; Michael Lepley; Cory Swingen; Liying Zhang; Dan S Kaufman; Jianyi Zhang
Journal:  Circ Res       Date:  2012-06-21       Impact factor: 17.367

3.  Comparative Efficacy of Intracoronary Allogeneic Mesenchymal Stem Cells and Cardiosphere-Derived Cells in Swine with Hibernating Myocardium.

Authors:  Brian R Weil; Gen Suzuki; Merced M Leiker; James A Fallavollita; John M Canty
Journal:  Circ Res       Date:  2015-08-13       Impact factor: 17.367

4.  Cell Therapy: Targeting Endogenous Repair Versus Remuscularization.

Authors:  Konstantinos E Hatzistergos; Joshua M Hare
Journal:  Circ Res       Date:  2015-09-25       Impact factor: 17.367

5.  Moving beyond surrogate endpoints in cell therapy trials for heart disease.

Authors:  Konstantinos Malliaras; Eduardo Marbán
Journal:  Stem Cells Transl Med       Date:  2013-11-29       Impact factor: 6.940

Review 6.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

7.  Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial.

Authors:  Vasileios Karantalis; Darcy L DiFede; Gary Gerstenblith; Si Pham; James Symes; Juan Pablo Zambrano; Joel Fishman; Pradip Pattany; Ian McNiece; John Conte; Steven Schulman; Katherine Wu; Ashish Shah; Elayne Breton; Janice Davis-Sproul; Richard Schwarz; Gary Feigenbaum; Muzammil Mushtaq; Viky Y Suncion; Albert C Lardo; Ivan Borrello; Adam Mendizabal; Tomer Z Karas; John Byrnes; Maureen Lowery; Alan W Heldman; Joshua M Hare
Journal:  Circ Res       Date:  2014-02-24       Impact factor: 17.367

Review 8.  Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges.

Authors:  Luiza Bagno; Konstantinos E Hatzistergos; Wayne Balkan; Joshua M Hare
Journal:  Mol Ther       Date:  2018-05-25       Impact factor: 11.454

9.  A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy.

Authors:  Umesh C Sharma; Swati D Sonkawade; Joseph A Spernyak; Sandra Sexton; Juliane Nguyen; Suraj Dahal; Kristopher M Attwood; Anurag K Singh; Jop H van Berlo; Saraswati Pokharel
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

10.  Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction.

Authors:  Marcin Wysoczynski; Mitesh Solanki; Sylwia Borkowska; Patrick van Hoose; Kenneth R Brittian; Sumanth D Prabhu; Mariusz Z Ratajczak; Gregg Rokosh
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.